The researchers were interested in the enzyme
7,8-diaminopelargonic acid synthase (BioA) from Mycobacterium tuberculosis, the organism that causes its eponymous
disease. This enzyme – which is not found in mammals – is involved in the
synthesis of the essential cofactor biotin. DSF was used to screen 1000
compounds from the Maybridge Ro3 Diversity Fragment Library at 5 mM
concentration, resulting in 21 hits which changed the denaturation temperature
(Tm) by more than 2 °C.
A dozen of these decreased the Tm, but although all of these were
taken into crystallography trials, only compound 1 yielded a structure. STD NMR
was also used to confirm that the compound binds to BioA in solution.
Next, the researchers used the classic “SAR-by-catalog”
approach and purchased analogs of compound 1. Compound 2 turned out to be
particularly interesting: it decreased the Tm by a whopping 18 °C! Weirder still, when soaked
into crystals of BioA, they turned from yellow to red.
BioA is a transaminase: it takes a nitrogen from one molecule (called SAM) and transfers it to another molecule (called KAPA). En route to its final destination, the nitrogen is transferred to a co-factor, pyridoxal phosphate (PLP), which contains an aldehyde. Compound 2 contains a hydrazine, which is known to react with aldehydes, and in fact a co-crystal structure of compound 2 bound to BioA shows that this is exactly what happens. Interestingly, compound 2 binds in a somewhat different manner than compound 1 despite their similar chemical structures.
BioA is a transaminase: it takes a nitrogen from one molecule (called SAM) and transfers it to another molecule (called KAPA). En route to its final destination, the nitrogen is transferred to a co-factor, pyridoxal phosphate (PLP), which contains an aldehyde. Compound 2 contains a hydrazine, which is known to react with aldehydes, and in fact a co-crystal structure of compound 2 bound to BioA shows that this is exactly what happens. Interestingly, compound 2 binds in a somewhat different manner than compound 1 despite their similar chemical structures.
Compound 2 turns out to be a reversible inhibitor of BioA, and the researchers were able to demonstrate that it is a moderately potent and competitive inhibitor with respect to SAM and a less potent uncompetitive inhibitor with respect to KAPA. This is exactly what you would expect, since it competes with SAM for binding to PLP but does not compete with KAPA.
Now you may think that hydrazines aren’t exactly drug-like,
but it turns out that a commonly used drug against tuberculosis is isoniazid,
which contains an analogous acyl hydrazide. The researchers found that
isoniazid also decreases the Tm of BioA, though less dramatically
than compound 2. Though isoniazid works through an entirely different mechanism,
the researchers were able to obtain a co-crystal structure of this binding to
PLP in BioA (magenta; PLP is on the left, and protein is not shown), showing
that it binds differently than either compound 1 (green) or 2 (cyan).
Nonetheless, it did not show any inhibition of the enzyme, demonstrating that
covalent binding alone is not sufficient for disrupting enzymatic activity.
This is a very nice paper, and it will be fascinating to try
to understand how the fragments so effectively destabilize the protein despite
binding tightly, and how this translates into inhibition. The researchers
suggest that finding ligands that destabilize proteins could be generally useful
for turning off proteins. Are there other well-characterized examples out there?
Nice Synopsis, Dan. Thanks for calling attention to this.
ReplyDeleteWe original suspected that the destabilizing hits were displacing the PLP (which is wildly stabilizing), but this proved - at least in the case of compound 1 - entirely wrong